Correction to: Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials

Masahiro Nomoto¹ · Hirotaka Iwaki² · Hiroyuki Kondo³ · Masaya Sakurai³

Published online: 21 December 2017
© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Correction to: Journal of Neurology
<https://doi.org/10.1007/s00415-017-8671-0>

Unfortunately, the online published article has errors in Table 1 and Table 2. The corrected tables are given in the following page.

The original article can be found online at <https://doi.org/10.1007/s00415-017-8671-0>.

✉ Masahiro Nomoto
nomoto@m.ehime-u.ac.jp

¹ Department of Neurology and Clinical Pharmacology, Ehime University Hospital, Shitsukawa, Toon, Ehime, Japan

² Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan

³ Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan

Table 1 Baseline characteristics in (A) full analysis set and (B) safety set in (a) combination therapy with levodopa and (b) monotherapy

(A)						
(a) Combination therapy with levodopa						
	Elderly		Non-elderly			
	Rotigotine	Placebo	Rotigotine	Placebo		
	<i>n</i>	<i>n</i>	<i>n</i>	<i>n</i>		
Age (years), mean ± SD	86	73.6 ± 2.8	68	73.2 ± 2.7	164	61.3 ± 6.9
Weight (kg), mean ± SD	86	52.7 ± 11.4	68	57.5 ± 10.6	164	56.1 ± 10.7
Duration of PD (years), mean ± SD	86	7.4 ± 6.4	68	6.2 ± 3.5	164	7.0 ± 4.6
Levodopa dose at first intervention (mg), mean ± SD	86	370.9 ± 180.9	68	342.6 ± 125.6	164	356.1 ± 145.5
Sex (male), number (%)	86	33 (38.4)	68	40 (58.8)	164	62 (37.8)
HY scale, number (%)						
0	—	—	—	—	—	—
1	—	—	—	—	—	—
1.5	—	—	—	—	—	—
2	86	16 (18.6)	68	15 (22.1)	164	40 (24.4)
2.5	86	14 (16.3)	68	12 (17.6)	164	45 (27.4)
3	86	47 (54.7)	68	33 (48.5)	164	65 (39.6)
4	86	9 (10.5)	68	8 (11.8)	164	14 (8.5)
5	—	—	—	—	—	—
UPDRS score, mean ± SD						
Part I	86	1.07 ± 1.34	68	1.18 ± 1.54	164	0.92 ± 1.46
Part II (on)	86	9.40 ± 5.59	68	9.24 ± 6.07	164	8.24 ± 5.84
Part II (off)	49	14.51 ± 8.36	42	16.55 ± 9.12	116	16.00 ± 8.91
Part II (average)	86	11.31 ± 5.78	68	11.57 ± 6.68	163	11.26 ± 6.36
Part III	86	27.59 ± 11.38	68	26.91 ± 10.46	164	26.10 ± 11.09
Part IV	86	2.87 ± 2.76	67	2.58 ± 2.35	164	3.48 ± 2.81

(b) Monotherapy								
	Elderly			Non-elderly				
	Rotigotine		Placebo	Rotigotine		Placebo		
	<i>n</i>		<i>n</i>	<i>n</i>		<i>n</i>		
Age (years), mean ± SD	28	73.3 ± 2.6	31	74.2 ± 3.0	60	61.3 ± 6.9	57	61.8 ± 6.0
Weight (kg), mean ± SD	28	55.2 ± 10.9	31	54.0 ± 8.7	60	56.8 ± 9.2	57	55.4 ± 9.5
Duration of PD (years), mean ± SD	28	1.3 ± 1.3	31	1.5 ± 1.7	60	2.3 ± 1.9	57	2.0 ± 2.0
Sex (male), number (%)	28	12 (42.9)	31	14 (45.2)	60	21 (35.0)	57	23 (40.4)
HY scale, number (%)								
0	–	–	–	–	–	–	–	–
1	28	2 (7.1)	31	0 (0.0)	60	10 (16.7)	57	5 (8.8)
1.5	28	3 (10.7)	31	5 (16.1)	60	5 (8.3)	57	7 (12.3)
2	28	11 (39.3)	31	14 (45.2)	60	23 (38.3)	57	22 (38.6)
2.5	28	5 (17.9)	31	5 (16.1)	60	6 (10.0)	57	7 (12.3)
3	28	7 (25.0)	31	7 (22.6)	60	16 (26.7)	57	16 (28.1)
4	–	–	–	–	–	–	–	–
5	–	–	–	–	–	–	–	–
UPDRS score, mean ± SD								
Part I	28	1.00 ± 1.66	31	0.81 ± 1.01	60	0.67 ± 1.05	57	0.44 ± 0.78
Part II	28	6.86 ± 4.72	31	8.03 ± 3.89	60	6.80 ± 3.56	57	7.12 ± 3.56
Part III	28	20.89 ± 9.06	31	20.90 ± 9.16	60	19.82 ± 9.36	57	20.74 ± 9.77
Part IV	28	0.25 ± 0.44	31	0.23 ± 0.43	60	0.32 ± 0.54	57	0.18 ± 0.38

(B)	(a) Combination therapy with levodopa								
	Elderly				Non-elderly				
	Rotigotine		Placebo		Rotigotine		Placebo		
	<i>n</i>		<i>n</i>		<i>n</i>		<i>n</i>		
	Age (years), mean ± SD	87	73.6 ± 2.8	69	73.2 ± 2.6	168	61.4 ± 6.9	103	61.4 ± 7.0
	Weight (kg), mean ± SD	87	52.8 ± 11.4	69	57.3 ± 10.7	168	56.0 ± 10.6	103	57.5 ± 9.6
	Duration of PD (years), mean ± SD	87	7.3 ± 6.3	69	6.1 ± 3.5	168	6.9 ± 4.6	103	6.1 ± 3.9
	Levodopa dose at first intervention (mg), mean ± SD	87	370.1 ± 180.0	69	342.0 ± 124.7	168	365.4 ± 196.5	103	353.6 ± 149.8
	Sex (male), number (%)	87	34 (39.1)	69	40 (58.0)	168	62 (36.9)	103	47 (45.6)
	HY scale, number (%)								
	0	–	–	–	–	–	–	–	–
	1	–	–	–	–	–	–	–	–
	1.5	–	–	–	–	–	–	–	–
	2	87	16 (18.4)	69	16 (23.2)	168	41 (24.4)	103	22 (21.4)
	2.5	87	14 (16.1)	69	12 (17.4)	168	45 (26.8)	103	25 (24.3)
	3	87	48 (55.2)	69	33 (47.8)	168	66 (39.3)	103	49 (47.6)
	4	87	9 (10.3)	69	8 (11.6)	168	16 (9.5)	103	7 (6.8)
	5	–	–	–	–	–	–	–	–
	UPDRS score, mean ± SD								
	Part I	87	1.07 ± 1.33	69	1.19 ± 1.34	168	0.96 ± 1.49	103	0.70 ± 1.03
	Part II (on)	87	9.41 ± 5.56	69	9.17 ± 6.05	168	8.33 ± 5.91	103	7.18 ± 5.45
	Part II (off)	50	14.62 ± 8.31	43	16.40 ± 9.07	118	15.99 ± 8.84	76	13.95 ± 6.78
	Part II (average)	87	11.36 ± 5.76	69	11.51 ± 6.65	167	11.31 ± 6.35	103	10.11 ± 5.30
	Part III	87	27.77 ± 11.43	69	26.68 ± 10.56	168	26.47 ± 11.57	103	25.45 ± 10.34
	Part IV	87	2.90 ± 2.76	68	2.60 ± 2.34	168	3.46 ± 2.81	103	3.35 ± 2.38

(b) Monotherapy						
	Elderly			Non-elderly		
	Rotigotine		Placebo	Rotigotine		Placebo
	<i>n</i>		<i>n</i>	<i>n</i>		<i>n</i>
Age (years), mean ± SD	30	73.3 ± 2.5	31	74.2 ± 3.0	60	61.3 ± 6.9
Weight (kg), mean ± SD	30	55.0 ± 10.5	31	54.0 ± 8.7	60	56.8 ± 9.2
Duration of PD (years), mean ± SD	30	1.3 ± 1.3	31	1.5 ± 1.7	60	2.3 ± 1.9
Sex (male), number (%)	30	13 (43.3)	31	14 (45.2)	60	21 (35.0)
HY scale, number (%)						
0	–	–	–	–	–	–
1	30	2 (6.7)	31	0 (0.0)	60	10 (16.7)
1.5	30	3 (10.0)	31	5 (16.1)	60	5 (8.3)
2	30	13 (43.3)	31	14 (45.2)	60	23 (38.3)
2.5	30	5 (16.7)	31	5 (16.1)	60	6 (10.0)
3	30	7 (23.3)	31	7 (22.6)	60	16 (26.7)
4	–	–	–	–	–	–
5	–	–	–	–	–	–
UPDRS score						
Part I	30	1.03 ± 1.61	31	0.81 ± 1.01	60	0.67 ± 1.05
Part II	30	6.97 ± 4.57	31	8.03 ± 3.89	60	6.80 ± 3.56
Part III	30	20.73 ± 8.78	31	20.90 ± 9.16	60	19.82 ± 9.36
Part IV	30	0.30 ± 0.53	31	0.23 ± 0.43	60	0.32 ± 0.54
						0.17 ± 0.38

SD standard deviation, HY scale modified Hoehn and Yahr scale, UPDRS score Unified Parkinson's Disease Rating Scale score

Table 2 Cumulative incidences of adverse events for (A) rotigotine treatment and (B) placebo: those occurring $\geq 5\%$, and those defined as remarkable adverse events

(A)

Adverse event (PT)	Combination therapy (levodopa with rotigotine)				Monotherapy (rotigotine)			
	Elderly (n = 87)		Non-elderly (n = 168)		Elderly (n = 30)		Non-elderly (n = 60)	
	n	Ratio (%)	n	Ratio (%)	n	Ratio (%)	n	Ratio (%)
Total	76	87.4	155	92.3	24	80.0	54	90.0
Application site reactions	37	42.5	98	58.3	10	33.3	32	53.3
Nasopharyngitis	17	19.5	29	17.3	4	13.3	7	11.7
Nausea ^a	15	17.2	27	16.1	2	6.7	19	31.7
Dyskinesia	9	10.3	30	17.9	0	0.0	1	1.7
Somnolence ^a	6	6.9	17	10.1	6	20.0	7	11.7
Visual hallucination ^a	8	9.2	13	7.7	1	3.3	2	3.3
Vomiting ^a	6	6.9	14	8.3	2	6.7	12	20.0
Contusion	7	8.0	6	3.6	1	3.3	0	0.0
Loss of appetite	5	5.7	7	4.2	2	6.7	3	5.0
Blood creatinine phosphokinase increase	3	3.4	9	5.4	1	3.3	3	5.0
Application site pruritus	5	5.7	6	3.6	0	0.0	0	0.0
Dizziness	7	8.0	4	2.4	0	0.0	0	0.0
Fall	5	5.7	5	3.0	0	0.0	0	0.0
Orthostatic hypotension ^a	1	1.1	6	3.6	0	0.0	0	0.0
Hallucination ^a	4	4.6	2	1.2	4	13.3	0	0.0
Auditory hallucination ^a	0	0.0	3	1.8	0	0.0	0	0.0
Delusion ^a	1	1.1	2	1.2	0	0.0	0	0.0
Sudden onset of sleep ^a	1	1.1	0	0.0	1	3.3	0	0.0
Constipation	3	3.4	8	4.8	3	10.0	9	15.0
Insomnia	0	0.0	6	3.6	2	6.7	4	6.7
Back pain	0	0.0	6	3.6	2	6.7	1	1.7
Diarrhea	2	2.3	2	1.2	0	0.0	3	5.0
Weight loss	1	1.1	2	1.2	2	6.7	0	0.0
Peripheral edema	1	1.1	1	0.6	2	6.7	0	0.0
Hypokalemia	0	0.0	0	0.0	2	6.7	0	0.0
				–				0.0431

(B)

Adverse event (PT)	Combination therapy (levodopa with placebo)				Monotherapy (placebo)			
	Elderly (n = 69)		Non-elderly (n = 103)		Elderly (n = 31)		Non-elderly (n = 59)	
	n	Ratio (%)	n	Ratio (%)	n	Ratio (%)	n	Ratio (%)
Total	53	76.8	83	80.6	19	61.3	46	78.0

Adverse event (PT)	Combination therapy (levodopa with placebo)				Monotherapy (placebo)			
	Elderly (<i>n</i> = 69)		Non-elderly (<i>n</i> = 103)		Elderly (<i>n</i> = 31)		Non-elderly (<i>n</i> = 59)	
	<i>n</i>	Ratio (%)	<i>n</i>	Ratio (%)	<i>n</i>	Ratio (%)	<i>n</i>	Ratio (%)
Application site reactions	9	13.0	17	16.5	6	19.4	14	23.7
Nasopharyngitis	11	15.9	15	14.6	4	12.9	11	18.6
Nausea ^a	4	5.8	8	7.8	0	0.0	5	8.5
Dyskinesia	3	4.3	5	4.9	0	0.0	0	0.0
Somnolence ^a	1	1.4	2	1.9	1	3.2	3	5.1
Visual hallucination ^a	2	2.9	3	2.9	0	0.0	0	0.0
Vomiting ^a	1	1.4	2	1.9	1	3.2	0	0.0
Contusion	2	2.9	7	6.8	3	9.7	4	6.8
Loss of appetite	1	1.4	2	1.9	0	0.0	0	0.0
Blood creatinine phosphokinase increase	1	1.4	3	2.9	1	3.2	1	1.7
Application site pruritus	2	2.9	2	1.9	0	0.0	0	0.0
Dizziness	1	1.4	2	1.9	2	6.5	2	3.4
Fall	2	2.9	6	5.8	1	3.2	1	1.7
Orthostatic hypotension ^a	4	5.8	2	1.9	0	0.0	1	1.7
Hallucination ^a	2	2.9	1	1.0	0	0.0	0	0.0
Auditory hallucination ^a	0	0.0	1	1.0	0	0.0	0	0.0
Delusion ^a	0	0.0	0	0.0	0	0.0	0	0.0
Sudden onset of sleep ^a	0	0.0	0	0.0	0	0.0	0	0.0
Constipation	2	2.9	1	1.0	1	3.2	4	6.8
Insomnia	2	2.9	2	1.9	0	0.0	2	3.4
Back pain	2	2.9	4	3.9	0	0.0	1	1.7
Diarrhea	1	1.4	2	1.9	2	6.5	1	1.7
Weight loss	0	0.0	0	0.0	0	0.0	0	0.0
Peripheral edema	1	1.4	3	2.9	0	0.0	0	0.0
Hypokalemia	0	0.0	0	0.0	0	0.0	0	0.0

^aSymptom defined as a remarkable adverse event[†]For comparison between elderly and non-elderly groups